Medtronic Announces Pricing of Offering and Redemption of Senior Notes

Details

Additionally, Medtronic Luxco elected to redeem all of its outstanding 2.625% Senior Notes due 2025 on September 29, 2025. The net proceeds from the Offering will be used to repay the 0.000% Senior Notes due 2025 and the 2.625% Senior Notes due 2025. The Offering involves the issuance and sale of 2.950% Senior Notes due 2030 and 4.200% Senior Notes due 2045, with the Notes guaranteed by Medtronic Luxco and Medtronic plc.

Items reported

About Medtronic plc

Medtronic plc is a leading global healthcare technology company that designs, manufactures, and sells innovative medical devices and therapies used in various medical procedures. The primary function of Medtronic is to improve healthcare outcomes by providing advanced therapeutic solutions. Its extensive product portfolio includes cardiac and vascular devices, diabetes-related products, minimally invasive therapies, and neurosurgical technologies. Medtronic plays a vital role in the medical device industry, catering to cardiovascular treatment, advanced diabetes management, spinal and musculoskeletal therapy, and more. Notably, the company is renowned for its pacemaker technology and is a pivotal player in cardiac care. The company's innovations significantly impact the healthcare sector by enhancing the quality of life for patients worldwide and improving the effectiveness of medical treatments. As a key player in the medical device market, Medtronic is instrumental in setting industry standards and advancing medical technology through continuous research and development. Founded in 1949 and headquartered in Dublin, Ireland, Medtronic's global presence underscores its substantial contribution to the healthcare industry across various continents.